Impaired high density lipoprotein antioxidant activity in healthy postmenopausal women

Atherosclerosis

Volumn 177, Issue 1, 2004, Pages 203-210

  Zago, Valeria ^a   Sanguinetti, Silvia ^a   Brites, Fernando ^a   Berg, Gabriela ^a   Verona, Julián ^a   Basilio, Francisco ^a   Wikinski, Regina ^a   Schreier, Laura ^a  

^a Fac Cie Exact Y Nat Univ B   (Argentina)

Author keywords

Antioxidant activity; High density lipoprotein; Oxidation; Paraoxonase; Postmenopause

Indexed keywords

ALPHA TOCOPHEROL; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER TRANSFER PROTEIN; COPPER; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CHEMICAL COMPOSITION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; NORMAL HUMAN; OXIDATION; PHENOTYPE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADULT; ALPHA-TOCOPHEROL; ARYLDIALKYLPHOSPHATASE; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; GLYCOPROTEINS; HUMANS; LIPOPROTEINS, HDL; MIDDLE AGED; OXIDATION-REDUCTION; POSTMENOPAUSE;

EID: 5444266732     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.07.011     Document Type: Article

References (42)

1. W.B. Kannel Metabolic risk factors for coronary artery disease in women: prospective from the Framingham study Am Heart J 114 1987 413 419
2. A. Wakatsuki, and Y. Sagara Lipoprotein metabolism in postmenopausal and oophorectomized women Obstet Gynecol 85 1995 523 528
3. G.A. Berg, N. Siseles, A.I. González, O. Contreras Ortiz, A. Tempone, and R.W. Wikinski Higher values of hepatic lipase activity in postmenopause: relationship with atherogenic intermediate density and low density lipoproteins Menopause 8 2001 51 57
4. D. Steinberg, and J.L. Witztum Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105 2002 2107 2111
5. Heart protection Study Collaborative Group MRC/BHF heart protection study of antioxidant vitamin supplementation in 20536 high-risk individuals: randomized placebo-controlled trial Lancet 360 2002 23 33
6. S. Hulley, D. Grady, and T. Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
7. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
8. M.J. Tikkanen, V. Vihma, M. Jauhiainen, A. Hockerstedt, H. Helisten, and M. Kaamanen Lipoprotein-associated estrogens Cardiovasc Res 56 2002 184 188
9. M. Mackness, S. Arrol, C. Abbot, and P. Durrington Protection of low density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase Atherosclerosis 104 1993 129 135
10. S.M. Sanguinetti, F.D. Brites, and V. Fasulo HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients Diab Nutr Metab 14 2001 27 36
11. A. Wakatsuki, N. Ikenoue, and Y. Sagara Effects of estrogen on susceptibility to oxidation of low-density and high-density lipoprotein in postmenopausal women Maturitas 28 1998 229 234
12. V. Schumaker, and D. Puppione Sequential flotation ultracentrifugation J.P. Segrest J.J. Alberts Methods in enzimology vol. 128 1986 Academic Press London 155 160
13. R. Noble Electrophoretic separation of plasma lipoproteins in agarose gel J Lipid Res 9 1968 693 700
14. 2 Clin Chem 29 1983 2026 2030
15. G. Assman, H. Jabs, U. Kohnert, W. Nolte, and H. Schriewer LDL (low density lipoprotein) cholesterol determination in blood serum following precipitation of LDL with poly(vinyl sulphate) Clin Chim Acta 140 1984 77 83
16. G. Bartlett Phosphorus assay in column chromatography J Biol Chem 234 1959 466 468
17. M.A. Markwell, S.M. Hass, L.L. Bieber, and N.E. Tolbert A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples Anal Biochem 87 1978 206 210
18. P. Motchnik, B. Frei, and B. Ames Measurement of antioxidants in human blood plasma Methods Enzymol 186 1994 269 279
19. L. Lagrost, H. Gandjini, A. Athias, V. Guyard-Dangremont, C. Lallemant, and P. Gambert Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects Arterioscler Thromb 13 1993 815 825
20. L.E. Schreier, S. Sanguinetti, H. Mosso, G. Lopez, L. Siri, and R. Wikinski Low-density lipoprotein composition and oxidability in atherosclerotic cardiovascular disease Clin Biochem 29 1996 479 487
21. H. Esterbauer, and G. Jurgens Mechanistic and genetic aspects of susceptibility of LDL to oxidation Curr Opin Lipidol 4 1993 114 124
22. C. Furlong, R. Richter, S. Seidel, L. Costa, and A. Motulski Spectrophotometric assay for the enzymatic hydrolysis of the active metabolites of cholpyrifos and parathion by plasma paraoxonase/arylesterase Anal Biochem 180 1989 242 247
23. B. La Du, and H. Eckerson The polymorphic paraoxonase/arylesterase isozymes of human serum Fed Proc 43 1984 2338 2341
24. W.P. Castelli Cardiovascular disease in women Am J Obstet Gynecol 158 1988 1553 1560
25. M. Leal, J. Diaz, E. Serrano, J. Abellán, and L.F. Carbonell Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes Obstetr Gynecol 95 2000 804 809
26. R.S. Sohal, R.J. Mockett, and W.C. Orr Mechanisms of aging: an appraisal of the oxidative stress hypothesis Free Radic Biol Med 33 2002 575 586
27. J. Regnström, J. Nilsson, P. Tornvall, C. Landou, and A. Hamsten Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man Lancet 339 1992 1183 1186
28. B. Garner, P. Witting, A. Waldeck, J. Christison, M. Raftery, and R. Stocker Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by α-tocopherol J Biol Chem 273 1998 6080 6087
29. S. Eisenberg High density lipoprotein metabolism J Lipid Res 25 1984 1017 1058
30. L. Jaouad, C. Milochevitch, and A. Khalil PON 1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity Free Radic Res 37 1 2003 77 83
31. J. Maziere, J. Myara, and S. Salmon Copper- and malondialdehyde-induced modification of high density lipoprotein and parallel loss of lecithin cholesterol acyltransferase activation Atherosclerosis 104 1993 213 219
32. Y. Nagano, H. Arai, and T. Kita High density lipoprotein losses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification Proc Natl Acad Sci USA 88 1991 6457 6461
33. B. Mackness, P.N. Durrington, B. Abuashia, A.J.M. Boulton, and M.I. Mackness Low paraoxonase activity in type II diabetes complicated by retinopathy Clin Sci 98 2000 355 363
34. T.F. Dautoine, J. Debord, and J.P. Charmes Decrease of serum paraoxonase activity in chronic renal failure J Am Soc Nephrol 9 1998 2082 2088
35. B. Mackness, M.I. Mackness, and S. Arrol Serum paraoxonase (PON 1) 55 and 192 polimorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus Atherosclerosis 139 1998 341 349
36. M. Dessi, A. Gnasso, and C. Motti Influence of the human paraoxonase polymorphism (PON-1 192) on the carotid-wall thickening in a healthy population Coron Artery Dis 10 1999 595 599
37. B.F. Asztalos, and E.J. Schaefer High-density lipoprotein subpopulations in pathologic conditions Am J Cardiol 91 Suppl 2003 12E 17E
38. J.D. Otvos, E.J. Jeyarajah, and W.C. Cromwell Measurement issues related to lipoprotein heterogeneity Am J Cardiol 90 2002 221 291
39. P.N. Durrington, B. Mackness, and M.I. Mackness Paraoxonase and atherosclerosis Arterioscler Thromb Vasc Biol 21 2001 473 480
40. A. Von Eckardstein, K. Schmiddem, and A. Hövels Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activity Atherosclerosis 159 2001 433 439
41. A.R. Genazzani, and M. Gambacciani Hormone replacement therapy: the perspectives for the 21st century. Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop Climacteric 3 2000 233 240
42. N.H. Hodis, W.J. Mack, and R. Lobo Estrogen in the provention of atherosclerosis Ann Int Med 135 2001 939 953